Glucotrack to File Pivotal US Clinical Trial IDE with FDA in Early Q2, Citing Strong Brazil Trial Data
GCTK sits 20% above its 52-week low of $1.01 on light trading volume (0.2× avg).
Summary
Glucotrack announced its intent to file a significant Investigational Device Exemption (IDE) with the FDA in early Q2 2026 for a US clinical trial of its novel continuous blood glucose monitoring (CBGM) technology. This critical regulatory step is supported by positive results from its first-in-human study in Brazil, which achieved a Mean Absolute Relative Difference (MARD) of 7.7% and a 99% data capture rate with no serious adverse events. The company has also completed readiness activities, including securing a US clinical trial site and engaging a Clinical Research Organization. For a micro-cap medical technology firm, this represents a major advancement towards commercialization in the US market, indicating progress in its core product pipeline. The next key catalyst will be the actual IDE submission and subsequent FDA approval, which would allow the company to initiate the US clinical study in the second half of 2026.
At the time of this announcement, GCTK was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $1.01 to $16.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.